

Supplementary material

Niedziela JT, Hiczkiewicz J, Kleinrok A, et al. Prevalence, characteristics, and prognostic implications of type 2 diabetes in patients with myocardial infarction: the Polish Registry of Acute Coronary Syndromes (PL-ACS) annual 2018 report. Kardiol Pol. 2020; 78: 247-250. doi:10.33963/KP.15189

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Parameter	DM (n = 7323)	No DM (n = 18 425)	P value
In-hospital treatment			
Coronary angiography, %	96.0 (7,019)	97.4 (17,928)	<0.001
MVD, % *	43.5 (3,040/6983)	35.6 (6,363/17,842)	<0.001
LM IRA, % *	3.5 (246/7,019)	2.5 (439/17,928)	0.005
PCI, % *	82.1 (5,750/7,009)	82.9 (14,837/17,903)	0.08
CABG direct, % *	4.4 (305/7,001)	3.5 (619/17,894)	<0.001
CABG after discharge, % *	4.4 (313/7,001)	3.3 (591/17,894)	<0.001
GP IIb/III, % *	11.7 (813/6,931)	15.7 (2,785/17,741)	<0.001
Inotropes, %	6.3 (453/7,225)	5.1 (923/18,242)	<0.001
ASA, %	93.9 (6,833/7,276)	92.7 (17,004/18,334)	<0.001
Second antiplatelet drug, %	79.8 (5,841/7,323)	79.4 (14,638/18,425)	0.57
Clopidogrel, %	62.6 (4,539/7,252)	57.6 (10,539/18,238)	<0.001
Ticagrelor, %	18.0 (1,306/7,253)	22.9 (4,187/18,312)	<0.001

Treatment at discharge			
Beta-blocker, %	83.2 (6,037/7,259)	81.2 (14,832/18,271)	<0.001
ACEI or ARB or ARNI, %	77.4 (5,670/7,323)	75.4 (13,886/18,425)	<0.001
MRA, %	15.4 (1,114/7,257)	11.8 (2,163/18,264)	<0.001
Diuretic, %	50.5 (3,668/7,257)	32.9 (6,005/18,264)	<0.001
Statin, %	76.9 (5,634/7,323)	72.7 (13,388/18,425)	<0.001
ASA, %	91.6 (6,654/7,264)	92.2 (16,850/18,269)	0.09
Second antiplatelet drug, %	80.6 (5,900/7,323)	80.2 (14,771/18,425)	0.47
Clopidogrel, %	61.5 (4,613/7,263)	55.9 (10,544/18,272)	<0.001
Ticagrelor, %	17.0 (1,236/7,262)	22.7 (4,142/18,275)	<0.001
Oral anticoagulants, %	12.7 (928/7,323)	8.5 (1,562/18,425)	<0.001
Calcium blocker, %	20.0 (1,485/7,256)	13.1 (2,390/18,264)	<0.001
Nitrates, %	8.2 (592/7,257)	6.9 (1,252/18,262)	<0.001
PPI, %	60.4 (4,228/7,260)	56.2 (10,269/18,269)	<0.001
In-hospital treatment of diabetes (patients with DM only)			
Parameter	DM and LVEF<40% n=2,084	DM and LVEF≥40% n=6,648	P values
No DM drugs, %	13.7 (194/1,421)	12.7 (587/4,605)	0.37
Oral antidiabetic, %	46.1 (657/1,425)	55.5 (2,559/4,609)	<0.001
Insulin, %	52.5 (743/1,416)	42.1 (1,928/4,585)	<0.001
Sulphonylurea, %	41.2 (271/657)	40.8 (1,045/2,559)	0.85
Biguanide, %	51.6 (339/657)	56.7 (1,451/2,559)	0.02
Alpha-glucosidase inhibitors,	2.7 (18/657)	2.9 (73/2,559)	0.88

%			
Thiazolidinediones, %	0.3 (2/657)	0.2 (5/2559)	0.95**
DPP-4 inhibitor, %	0.3 (2/657)	0.6 (16/2,559)	0.49**
GLP-1 RA, %	0.9 (6/657)	0.9 (23/2559)	0.84
Other, %	14.8 (97)	13.2 (338/2,559)	0.30
Diabetes treatment on discharge (patients with DM only)			
Parameter	DM and LVEF<40% n=1,891	DM and LVEF≥40% n=6,539	P values
No DM drugs, %	24.1 (344/1,426)	18.0 (830/4,612)	<0.001
Oral antidiabetic drug, %	43.1 (614/1,426)	59.3 (2,735/4,612)	<0.001
Insulin, %	40.9 (582/1,424)	34.1 (1,572/4,609)	<0.001
Sulphonylurea, %	18.3 (260 /1,424)	23.5 (1,083/4,609)	<0.001
Biguanide, %	24.4 (347/1,423)	36.3 (1,674/4,609)	<0.001
Alpha-glucosidase inhibitors, %	0.6 (9/1,423)	1.3 (60/4,609)	0.05**
Thiazolidinediones, %	0.1 (1/1423)	0.1 (5/4,608)	0.94**
DPP-4 inhibitor, %	0.2 (4/1,423)	0.6 (30/4,609)	0.15**
GLP-1 RA, %	0.4 (6/1,423)	0.5 (24/4,609)	0.80**
Other, %	5.1 (72/1,423)	6.5 (299/4,609)	0.05
* Data for patients with coronary angiography performed			
** Yates correction			
Abbreviations: ACEI, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor; ASA, acetylsalicylic acid;			

CABG, coronary artery bypass graft; DM, diabetes mellitus; DPP-4, dipeptidyl peptidase 4; GLP-1 RA, glucagonlike peptide-1 receptor agonist; GP IIb/IIIa, glycoprotein IIb/IIIa; IRA, infarct-related artery; LM, left main; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; MVD, multi-vessel disease; NYHA, New York Heart Association functional classification; PCI, percutaneous coronary intervention